Robust neutralizing antibody response to SARS-CoV-2 mRNA vaccination in adolescents and young adults with childhood-onset rheumatic diseases.

Joo Guan YeoWan Ni ChiaKai Liang TehYun Xin BookSook Fun HohXiaocong GaoLena DasJinyan ZhangNursyuhadah SutamamAmanda Jin Mei LimSu Li PohShi Huan TayKatherine Nay YaungXin Mei OngSharifah Nur HazirahCamillus Jian Hui ChuaJing Yao LeongLin-Fa WangSalvatore AlbaniThaschawee Arkachaisri

Published in: Rheumatology (Oxford, England) (2022)

SARS-CoV-2 mRNA vaccines were efficacious after the two-dose regimen in almost all AYA with cRD without serious adverse event. The rate of disease flare observed is 4.4% after the second mRNA vaccine dose.

Keyphrases

sars cov
respiratory syndrome coronavirus
binding protein
dengue virus
early life
zika virus
adverse drug
young adults
childhood cancer